COVID-19 pneumonia and tocilizumab use
We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interle...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | Perú |
| Institución: | Universidad Nacional Mayor de San Marcos |
| Repositorio: | Revistas - Universidad Nacional Mayor de San Marcos |
| Idioma: | español |
| OAI Identifier: | oai:revistasinvestigacion.unmsm.edu.pe:article/17893 |
| Acceso en línea: | https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17893 |
| Access Level: | acceso abierto |
| Palabra clave: | Neumonía COVID-19 Interleucina-6 Tocilizumab Pneumonia Interleukin-6 |
| Sumario: | We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interleukin-6 receptor antagonist (tocilizumab) for compassionate use, obtaining a favorable clinical response. |
|---|